I believe that one should be vigilant in this disease. With that said I had a follow-up PSMA PET/CT March 13, 2023. It demonstrated a PSMA avid lesion anterior to L3 and behind the Aorta, consensus was that this did not represent an anatomical variant of the celiac ganglion.
My PSA was at the time <0.01 ng/ml by the Mayo Clinic Rochester Lab.
My first response to Dr. Kwon when discussing this lesion was yes you have permission to add me to the case series of individuals with these type of metastasis.
Review of my profile will show that I was a Gleason 9 at my diagnosis and clearly my tumor is devolving or evolving based on your perspective. It now makes little PSA but still retains PSMA markers.
My decision after discussions with Drs. Eugene Kwon, Ryan Phillips (both at Mayo) and Dr. Nat Lenzo (in Australia) is to proceed with fractionated radiation to the area which is near the boarder of my initial radiation field.
The primary decision in my mind was some form of SBRT vs more conventional radiation. In particular my discussions with Dr. Phillips persuaded me to go with more conventional radiation. Dr. Phillips has published on SBRT in prostate cancer and in particular oligometastatic prostate cancer and has been a self described advocate of this approach. However, he pointed out he is now privy to randomized data from a longitudinal study in progress that looks to support better long term results with more conventional fractionated radiation.
From a simplistic view this makes sense since radiation is most effective in late G2 and M phases of the cell cycle. Therefore more rapidly dividing cells more in sync would be most effectively treated by single dose radiation. Prostate cancer being notoriously slow in terms of division rate would have more vulnerable to radiation therapy by fractionating it over time to hopefully catch more of the cells in a vulnerable time of their cell cycle.
Do I think there is an absolute right answer? No. But I think you have to make the best decision you can with the available information you have from your own read of the literature and opinions collected from people you have grown to trust.
A secondary decision is should I follow up with Lu177. Dr. Lenzo is a firm advocate of this and Drs. Phillips and Kwan do not think it is a bad idea. Clearly this would mean taking a vacation overseas to achieve this both because I would not meet insurance criteria here and it would be more affordable. I am still thinking this over.
In the discussion of radioligand therapy I brought up the problem of renal toxicity. This is particularly a problem with Ac225 who's decay products, more than the primary molecule, seem be the source of problems. This issue is being addressed by Dr. S Takagawa at Weil Cornell where he and colleagues are working with Ac J591 which seems to have lower renal and salivary issues. I would suggest you google him and the isotope which will lead you to a talk by him on this subject.
Also since the issue of FDG scans repeatedly comes up on this forum I will pass on what I gleaned from discussions regarding this. Yes it might have a role in searching for neuroendocrine prostate cancer but not surprisingly Gallium-68 Dota-tate scans (also called NETSPOT scans) are probably more reliable in localizing and defining these lesions. This also opens the way for radioligand therapy similar to treatment of other neuroendocrine tumors with Lu177 Dota-tate.
I am sure there are those on this forum who will disagree with my chosen course but again I firmly believe we have to individually try to sort out how we are going to approach this disease.
To date my life quality has been good. And I am glad to say I managed to ski 51 days this season!!! So as long as I can remain enjoying life I will continue to pursue treatment.
Good luck to everyone who is truly struggling with this insidious awful disease.